Supernus Pharmaceuticals (SUPN) Amortization - Intangibles (2019 - 2026)

Supernus Pharmaceuticals (SUPN) has reported Amortization - Intangibles for 8 consecutive years, with $25.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Amortization - Intangibles rose 21.68% year-over-year to $25.3 million in Q2 2026; TTM through Jun 2026 was $95.0 million, a 21.26% increase from a year earlier, with the FY2025 full-year figure at $89.5 million, up 14.74% from the prior year.
• Amortization - Intangibles was $25.3 million for Q2 2026 at Supernus Pharmaceuticals, up from $24.6 million in the prior quarter.
• Over five years, Amortization - Intangibles peaked at $25.3 million in Q2 2026 and troughed at $18.3 million in Q4 2024.
• A 5-year average of $21.1 million and a median of $20.6 million in 2022 frame the typical range for Amortization - Intangibles.
• Across the five-year window, Amortization - Intangibles surged 247.07% in 2022 and declined 13.36% in 2024, its largest moves.
• Over 5 years, Amortization - Intangibles stood at $20.7 million in 2022, then rose by 1.86% to $21.1 million in 2023, then decreased by 13.36% to $18.3 million in 2024, then jumped by 34.5% to $24.6 million in 2025, then rose by 3.11% to $25.3 million in 2026.
• The last three Amortization - Intangibles figures came in at $25.3 million (Q2 2026), $24.6 million (Q4 2025), and $24.3 million (Q3 2025), per Business Quant data.